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BACKGROUND: JNJ-26483327 is an oral, potent, multi-targeted tyrosine kinase inhibitor, inhibiting kinases of epidermal growth factor
receptor (EGFR)-1, -2 and -4, rearranged during transfection (RET) receptor, vascular endothelial growth factor receptor (VEGFR)-3
and Src family (Lyn, Fyn, Yes) at low nanomolar concentrations. This phase I, accelerated titration study assessed maximum tolerated
dose, safety, pharmacokinetics and pharmacodynamic effects of JNJ-26483327.
METHODS: Nineteen patients with advanced cancers received JNJ-26483327 continuous twice daily (BID) in escalating dose cohorts
ranging from 100 to 2100mg. Pharmacodynamic effects were assessed in paired skin biopsies and blood.
RESULTS: JNJ-26483327 was well tolerated in doses up to 1500mg BID, with target-inhibition-related toxicity such as diarrhoea and
skin rash, and other common reported toxicities being nausea, vomiting, anorexia and fatigue. At 2100mg, two episodes of dose-
limiting toxicity were observed, consisting of grade 3 anorexia and a combination of grade 3 anorexia and fatigue, respectively.
Pharmacokinetics were dose proportional up to 1500mg in which plasma levels were obtained showing anti-tumour activity in
xenograft mouse models. Pharmacodynamic analysis did not show a substantial effect on expression of Ki-67, p27
kip1, phosphorylated
mitogen-activated protein kinase, phosphorylated Akt and EGFR, and serum levels of sVEGFR-2, VEGF-C and VEGF-D remained
unchanged. Stable disease was noted in six patients (32%).
CONCLUSION: JNJ-26483327 is well tolerated and shows a predictable pharmacokinetic profile; the recommended dose for further
studies is 1500mg BID.
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Protein kinases represent over 2% of all human genes and B9% of
known cancer genes. Overexpression or mutational and constitu-
tive activity of these kinases plays an important role in the
pathophysiology of tumours. Tyrosine kinase inhibitors (TKIs)
have become an emerging new class of anti-cancer agents because
of the importance of their targets in tumour proliferation, survival
(apoptosis), tumour neoangiogenesis, invasion and metastasis
(Blume-Jensen and Hunter, 2001; Shawyer et al, 2002). Significant
clinical successes have meanwhile been achieved with relatively
selective TKIs such as imatinib mesylate (Gleevec Glivec), erlotinib
(Tarceva), gefitinib (Iressa) and lapatinib (Tyverb) (Demetri et al,
2002; Fukuoka et al, 2003; Geyer et al, 2006; Perez-Soler, 2007) as
well as with the broad-spectrum TKIs sunitinib (Sutent) and
sorafenib (Nexavar) (Llovet et al, 2008; Escudier et al, 2009; Motzer
et al, 2009).
According to current understanding, most TKIs exert their
activity in a cytostatic manner, suggesting that prolonged and
maybe continuous treatment is to be recommended. Thus, an oral
route of administration is of clear advantage, and an adequate
oral bioavailability is a prerequisite (Eskens and Verweij, 2000).
Toxicities observed with the use of TKIs appear to be linked to
their primary mode of action (e.g. skin rash for EFGR inhibitors
because of epidermal growth factor receptor (EGFR)-kinase
inhibition in the basal layer of the skin), but other toxicities can
occur for which no clear-cut pathophysiologic explanation exists
as yet (Stadler, 2006).
JNJ-26483327 has displayed binding affinity to multiple tyrosine
kinase receptors known to play a role in a wide variety of
neoplasms. It showed potent (IC50 o10nM) in vitro inhibitory
activity against EGFR kinase, several mutationally activated EGFR
kinases and against RET-receptor kinase. Inhibitory activity
against vascular endothelial growth factor receptor (VEGFR)-3,
Her4 and Src family (Lyn, Fyn, Yes) tyrosine kinases was shown
over an IC50 range of 11–99nM. Other tyrosine kinases inhibited
by JNJ-26483327 (IC50 100–1000nM) include c-Src, Her2, Flt3 and
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sothers. In preclinical studies, anti-cancer activity was observed and
a favourable safety and tissue distribution profile was seen,
including passage of the blood–brain barrier. JNJ-26483327 is
administered as a twice daily (BID) oral regimen and has an oral
bioavailability of B80% (Johnson & Johnson, data on file).
This first-in-man study was designed to determine safety,
maximum tolerated dose (MTD) and dose-limiting toxicity (DLT)
of JNJ-26483327 in patients with refractory or advanced solid
tumours. In addition, the pharmacokinetic profile, pharmaco-
dynamic activity in various surrogate tissues and preliminary
signals of anti-tumour activity were assessed.
MATERIALS AND METHODS
Eligibility criteria
Patients with a histologically or cytologically confirmed diagnosis
of advanced solid malignancy for whom no standard options
existed or who were no longer responding to established treat-
ments were eligible. Additional eligibility criteria included age
X18 years; ECOG performance p2; life expectancy 43 months;
adequate bone marrow function, without the support of cytokines
and/or erythropoietin (white blood cell (WBC) count 43.0 10
9
per l, absolute neutrophil count 41.5 10
9 per l, platelet count
4100 10
9 per l, haemoglobin 410.0gdl
–1), hepatic function
(total bilirubin level p1.5 times institutional upper limit of normal
(iULN), serum alanine transferase and aspartate aminotransferase
p2.5 times iULN or p5 times iULN in case of liver metastases)
and renal function (serum creatinine o1.5 times iULN); no
chemotherapy, radiotherapy or immunotherapy within 28 days;
no history of uncontrolled heart disease or arterial hypertension
(systolic blood pressure X160mmHg and/or diastolic blood
pressure X100mmHg despite appropriate medication). Specific
exclusion criteria included a history of pulmonary fibrosis, known
central nervous system metastases, impairment of gastrointestinal
absorption status and inability to swallow. Left ventricular ejection
fraction (LVEF) based on MUGA scan was required to be 450%.
The study was approved by local ethics committees and all patients
gave written informed consent before any study-related procedure.
Study design
JNJ-26483327 was supplied by Johnson & Johnson Pharmaceutical
Research and Development, Beerse, Belgium as 10 or 50mgl
–1oral
solution for doses p1200mg, or capsules of 50, 100 or 300mg
for doses X1500mg. Medication was taken in combination with
food BID with 12h intervals. A cycle was defined as 28 days of
treatment.
The starting dose was 100mg BID, which was selected based
on preclinical data in rodents (one-third of the toxic dose low
and one-tenth of the dose causing severe toxicity in rat) and a
preceding study in healthy male volunteers. In the latter study,
JNJ-26483327 was safe and well tolerated with single doses up
to and including 200mg. On the basis of the observed half-life,
a BID-dosing regimen was chosen for this study.
The study followed an accelerated-escalation design. Initial
cohorts consisted of one patient with dose doublings between
cohorts in the absence of grade X2 toxicity according to the
National Cancer Institute Common Toxicity Criteria version 3.0
during the first cycle (http://ctep.cancer.gov/protocolDevelopment/
electronic_applications/docs/ctcaev3.pdf). Once grade X2 consid-
ered drug-related toxicity occurred during the first cycle, two
additional patients were enrolled at that dose level with subsequent
cohorts in accordance with a conventional dose-escalation (3þ3)
model. DLT was defined as any grade 3 or 4 non-haematological
toxicity, except for nausea, vomiting or diarrhoea responsive to
treatment; grade 3 skin rash/acne responsive to treatment, alopecia
and isolated grade 3 GGT elevations; need for loperamide for 47
days to treat or prevent grade X2d i a r r h o e a ;n e e df o rc o n t i n u o u s
administration of 5HT-3 antagonists for 47 days to treat or prevent
grade X2 nausea or vomiting; a relative decrease of LVEF on MUGA
scan of 420% compared with baseline; any grade 4 haematological
toxicity or treatment interruptions of 414 days for grade X2
toxicity in cycle 1.
If during the conventional escalation stage no DLT occurred, the
dose for the next cohort was incremented with 20–100%. If DLT
was observed during cycle 1 in one of three patients, an additional
three patients were enrolled at that dose level. If X2 out of 6
patients experienced DLT, the MTD was exceeded and three more
patients were enrolled at the next lower dose level, unless already
six patients had been accrued at that dose. The MTD was defined
as the highest dose at which less than one-third of the patients
experienced DLT.
No intrapatient dose escalation was allowed. In the absence of
DLT or disease progression, patients were allowed to continue on
JNJ-26483327 at the dose level assigned.
Pretreatment and follow-up studies
Prior to therapy, a complete medical history was taken and a
physical examination was performed. A complete blood cell (CBC)
count, WBC count and differential and serum biochemistry
including lipid profile and coagulation tests were performed,
as were urinalysis, a 12-lead electrocardiogram (ECG) and MUGA
scanning. Weekly evaluations during the first cycle, every other
week during the second cycle and monthly thereafter included
history, physical examination, adverse event assessment, CBC,
WBCþdifferential, serum chemistry, ECG and urinalysis. An ECG
was performed predose and 1, 2, 4, 8 and 24h postdose on days 1
and 28. Follow-up of LVEF by MUGA scanning was performed
at the end of the first and second cycle. Tumour measurements
were performed at baseline and during every other cycle. Response
was assessed according to RECIST (Therasse et al, 2000).
Pharmacokinetic sampling and data analysis
For pharmacokinetic analysis, blood samples (3ml) were collected
before dosing and 0.5, 1, 2, 3, 4, 6, 8 and 24h after drug
administration on days 1 and 28 and predose, 0.5, 1, 2, 4 and 6h
postdose on day 15 of the first cycle and day 28 of the second cycle.
Furthermore, trough PK samples were taken before drug adminis-
tration on days 8 and 22. Blood samples were collected and
protected from light in EDTA-Vacutainer
s tubes and plasma was
separated by centrifugation and stored at  201C within 2h of
collection. Plasma concentrations of JNJ-26483327 were deter-
mined by validated, selective and sensitive liquid chromatogra-
phy–mass spectrometry bioanalytical method. The PK parameters
gathered were area under the plasma concentration–time curve
from time zero and extrapolated to infinity (area under the curve,
AUCinf) after the first dose and calculated over the 12-h dose
interval tau at steady state (AUCtau), maximum observed plasma
concentration (Cmax), time to reach Cmax (tmax), apparent terminal
half-life (t1/2), apparent total plasma clearance (CL/F) and apparent
volume of distribution (Vdz/F).
Graphical analysis was performed using dose-normalised
Cmax as well as AUC of days 1 and 28 for exploration of dose
proportionality across doses.
Pharmacodynamic assessments
Modulation of EGFR, phosphorylated mitogen-activated protein
kinase (pMAPK), phosphorylated Akt (pAkt), Ki-67 (an indicator
of cellular proliferation) and p27
KIP1 (kinase inhibitory protein 1)
was assessed in skin biopsies at screening and on day 28 of the first
treatment cycle. Treatment-induced changes in these cellular
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formalin-fixed and paraffin-embedded skin tissue sections. Punch
biopsies (4mm width 4mm depth) were taken from the lateral
aspect of the upper extremity just before the first dose and at the
end of cycle 1. Specimens were immediately fixed in 10% buffered
neutral formalin for 16–24h, and embedded in paraffin. Tissue
sections (4mm) were mounted onto silan adhesive ‘Star Frost’ glass
slides (Waldemar Knittel Glaser, Braunschweig, Germany), dried
overnight at 501C, deparaffinised and rehydrated.
Antibodies used were monoclonal mouse anti-human Ki-67
antigen (clone MIB-1, DakoCytomation, Glostrup, Denmark);
monoclonal mouse anti-human p27
KIP1-protein (clone 1B4,
Monosan Sanbio, Uden, The Netherlands); phospho-p44/42 MAP
kinase (Thr202/Tyr204) antibody (#9101, Cell Signaling Technol-
ogy, Bioke ´, Leiden, The Netherlands); pAkt (Ser473) antibody
(#3787, Cell Signaling Technology); monoclonal mouse anti-EGFR
(clone E30, DakoCytomation). A pressure cooker-enhanced
procedure was used for antigen retrieval, except EGFR, which
required proteinase K treatment. Antigen detection and visualisa-
tion (Dako EnvisionþSystem-HRP, DakoCytomation, Glostrup,
Denmark) were according to the standard staining procedures as
provided by the manufacturer’s instructions. Positive and negative
control specimens were used for each IHC staining batch and, if
available, an appropriate blocking peptide was included as well.
Treatment effects of JNJ-26483327 on Ki-67 and p27
KIP1 were
assessed by counting X1000 positive keratinocytes and expressing
the markers as percentage. Regarding pMAPK-, pAkt- and EGFR-
positive keratinocytes, the proportion of positive cells as well as
the intensity of staining were estimated using the Allred scoring
system (Allred et al, 1998).
Blood samples were taken on day 1 before the first dose and on
days 15 and 28 in cycles 1 and 2. Blood was collected in a 6-ml
serum separator tube (Vacutainer
s SST No. 367784, Becton
Dickinson, Franklin Lakes, NJ, USA) and allowed to clot for
30min before centrifugation at 1000g. Serum was thereupon
removed, aliquotted into three separate 3.6ml cryotubes (Nunc,
Cat. No. 366524, Thermo Fisher Scientific, Rochester, NY, USA)
and stored at p 201C until further analysis. Treatment-induced
changes in serum levels of sVEGFR-2, VEGF-C and VEGF-D
were examined using specific Quantikine human VEGF Immuno-
assays (R&D systems Europe, Abingdon, UK; human sVEGFR-2
(DVR200), human VEGF-C (DVEC00), human VEGF-D
(DVED00)). Absolute concentrations of serum VEGF proteins
were determined according to the manufacturer’s protocol,
normalised to baseline levels and relative changes were correlated
to the administered dose of JNJ-26483327.
Statistical methods
The pharmacokinetic analysis and descriptive statistics were
performed using PKAA 2.00 (developed for J&JPRD). PKAA 2.00
uses WinNonLin 5.2.1. Elimination rate constants (lz) were
calculated as the negative of the slope of the terminal log-linear
segment of the plasma concentration–time curves. The range of
data used for each subject and dose were determined by visual
inspection of a semi-logarithmic plot of concentration vs time. At
least three data points were used to estimate lz. All PK calculations
and figures used validated software.
RESULTS
Nineteen patients (16 male, 3 female), with a median age of
61 years (47–74), were enrolled between October 2006 and July
2008. Patient demographics, baseline characteristics and prior
anti-cancer treatments are listed in Table 1.
A total of 44 cycles of JNJ-26483327 was administered, and the
maximum number of cycles received was six (received by two
subjects) with duration of treatment ranging from 11 to 168 days.
Dose levels studied were 100mg (n¼1), 200mg (n¼1), 400mg
(n¼1), 800mg (n¼3), 1200mg (n¼3), 1500mg (n¼6) and
2100mg (n¼4) (Table 2).
Safety
Occurrence of side effects, as a function of schedule and dose, is
listed in Table 3. Nausea, diarrhoea, vomiting, anorexia, fatigue
and skin rash were principal toxicities of JNJ-26483327.
Diarrhoea occurred in 460% of patients at all but the lowest
dose level was mostly mild or manageable with loperamide. One
patient (dose level 1500mg) experienced grade 3 diarrhoea that
quickly resolved after loperamide initiation. Other common
gastrointestinal side effects were nausea and, to a lesser extent,
vomiting, which was usually mild and only required specific
treatment in one patient. Eight patients complained of loss of
appetite, with frequency increasing with dose. In two patients
(dose level 2100mg) grade 3 anorexia was observed.
Cutaneous side effects manifested mainly as rash, occurring in
11 out of 19 patients, with a hint of dose dependency (6 out of 11
received X1500mg) and predominantly located on the chest
(Figure 1). Skin toxicity predominantly occurred during the
first cycle and was transient with ongoing treatment. Skin
Table 1 Patient characteristics
Total 19
Male/female 16/3
Median age (years) 61
Range (years) 47–74
Prior systemic therapy 18
Prior radiotherapy 5
Prior surgery 12
ECOG performance score
04
11 3
22
Tumour type
Colorectal carcinoma 6
Oesophageal carcinoma 5
Prostate carcinoma 2
Hepatocellular carcinoma 1
Mesothelioma 1
Renal cell carcinoma 1
ACUP 1
Cholangiocarcinoma 1
Thyroid carcinoma 1
Abbreviation: ECOG¼Eastern Cooperative Oncology Group.
Table 2 Dose escalation scheme, treatment duration
Dose level
(mg)
No. of
patients
Total no.
of cycles
No. of patients with
DLT in cycle 1
100 1 2 —
200 1 2 —
400 1 2 —
800 3 10 —
1200 3 4 —
1500 6 17 —
2100 4 7 2
Abbreviation: DLT¼dose-limiting toxicity. Administration scheme: JNJ 26483327
twice daily, continuously, 28 days per cycle.
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skin toxicities.
Another frequently observed toxicity was mild fatigue (47.4%
of patients). Haematological toxicity consisted of anaemia, with
grade 2 anaemia detected in three patients. None of the subjects
with paired LVEF measurements (n¼15) showed a significant
decrease in LVEF and no hypertension was noted.
Dose-limiting toxicity
At 2100mg, two episodes of DLT, consisting of grade 3 anorexia
and of a combination of grade 3 anorexia and fatigue, were
observed in one patient each. Other coinciding toxicities observed
in the latter patient were grade 2 nausea, vomiting and diarrhoea,
ultimately resulting in treatment interruption at day 11. All (four)
patients in the 2100-mg cohort had substantial difficulty with the
capsule load (seven capsules of 300mg BID). On the basis of these
combined observations, the dose of 2100mg was considered to be
intolerable and, therefore, the MTD was set at 1500mg BID. At this
dose, three additional patients were studied, none of whom
experienced DLT.
Pharmacokinetics
Plasma concentrations of JNJ-26483327 rapidly increased after
oral administration. Maximum plasma concentrations (Cmax)
were reached 2–3h after the first administration of the liquid
formulation (dose levels 800 and 1200mg) and up to 4h after
administration of the capsule formulation (dose levels 1500 and
2100mg). On day 1, Cmax and overall drug exposure (AUClast)
increased with increasing doses up to 1200mg. At this dose level,
peak concentrations were on average nearly 4mgml
–1. The 1500
and 2100mg dose groups showed lower Cmax-values in the order of
2mgml
–1 as well as a decrease in overall drug exposure. After the
peak, plasma concentrations declined biphasically. For all dose
levels, the terminal half-life was 5–8h.
At steady state (as determined on days 15 and 28), Cmax was
reached 1–2h after ingestion of liquid formulation and 2–5h after
administration of capsule formulation; Cmax and AUC increased
with increasing dose up to 1500mg, but not beyond this dose.
Dose-normalised Cmax and AUC of 1200mg liquid formulation and
1500mg capsule formulation were comparable. Table 4 displays
pharmacokinetic parameters of JNJ-26483327 for all dose levels on
days 1 and 28 of cycle 1. Mean plasma concentration vs time curves
of 1500mg BID JNJ-26483327 on days 1 and 28 of cycle 1 are
shown in Figure 2.
Pharmacodynamics
Upon treatment with JNJ-26483327, no evident histopathological
effects were observed in paired skin samples. Furthermore, no
consistent changes in EGFR-associated cell-signalling biomarkers
(EGFR, pMAPK or pAKT) and indicators of cellular differentiation
(p27
KIP1) and proliferation (Ki-67) were detected in keratinocytes
of 16 paired skin biopsies. Baseline-normalised serum levels of
sVEGFR-2, VEGF-C and VEGF-D were not affected by treatment.
Table 3 Principal JNJ-26483327-related side-effects
100mg
(n¼1)
200mg
(n¼1)
400mg
(n¼1)
800mg
(n¼3)
1200mg
(n¼3)
1500mg
(n¼6)
2100mg
(n¼4)
Total
(n¼19)
G 1/2 G 3/4 G 1/2 G 3/4 G 1/2 G 3/4 G 1/2 G 3/4 G 1/2 G 3/4 G 1/2 G 3/4 G 1/2 G 3/4 n %
Nausea 00001020306010 1 3 68.4
Diarrhoea 00101020203120 1 2 63.2
Rash 10100020103120 1 1 57.9
Vomiting 00001020203020 1 0 52.6
Fatigue 10000010103021 9 47.4
Anorexia 00000010103012 8 42.1
Anaemia 00101000100000 3 15.8
Dysphonia 00000000102000 3 15.8
Pain 00001000100000 2 10.5
Dry skin 00000000002000 2 10.5
Constipation 00000000101000 2 10.5
Weight decreased 00000010000010 2 10.5
Dyspepsia 00000000101000 2 10.5
Dry skin 00000000002000 2 10.5
Skin exfoliation (palms) 00000000001000 1 5 . 3
Skin discolouration 00100000000000 1 5 . 3
Figure 1 Skin toxicity after administration of JNJ-26483327.
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Six patients had stable disease lasting more than two cycles; the
median number of cycles in these patients was four (range 3–6).
One patient with prostate cancer treated at 800mg BID and
another patient with renal cell carcinoma treated at 1500mg BID
showed stable disease at the end of the fourth cycle. Stable disease
did not continue beyond six cycles of treatment. There was no
significant relationship between the occurrence of stable disease
lasting more than two cycles and dose, even though three out of six
patients received X1500mg JNJ-26483327 BID.
DISCUSSION
This study was the first-in-human study evaluating the feasibility
of oral administration of JNJ-26483327 given continuously BID.
Main objectives were to define its toxicity profile and MTD, as well
as the pharmacokinetic and pharmacodynamic properties in man.
JNJ-26483327 was well tolerated up to 1500mg BID, with most
common reported toxicities being nausea, vomiting, diarrhoea,
anorexia, fatigue and skin rash. Cutaneous and gastro-
intestinal side effects predominate in studies with EGFR TKIs
(Loriot et al, 2008; Hartmann et al, 2009). The exact pathogenesis
is still unclear, but as functional EGFR is crucial for maintaining
integrity of the gastrointestinal mucosa, for normal development
and physiology of the epidermis, as well as for mucosal repair,
inhibiting EGFR activity likewise can induce mucocutaneous side
effects (Lacouture, 2006; Playford et al, 2006; Li and Perez-Soler,
2009). The occurrence of these side effects can even be considered
to be indicative for true target inhibition. In this study, gastro-
intestinal side effects showed a 95% incidence. Diarrhoea, nausea
and vomiting occurred at most dose levels, but tended to be dose
dependent. In those patients experiencing diarrhoea, loperamide
treatment was always effective. Skin toxicity consisted of usually
mild rash, dry skin, skin exfoliation, erythema, skin discoloration
and paronychia with an overall incidence of 68%. The frequency
and/or type of skin event was not clearly dose dependent and in all
circumstances local treatment with moisturising ointments was
sufficient in controlling these effects. No treatment interruption
was indicated or felt necessary. Other observed side effects were
also mild, never exceeding grade 2. As JNJ-26483327 is a Her2
inhibitor potentially inducing cardiotoxicity, special attention was
given towards early recognition of this phenomenon (Perez, 2008).
In this study, no signs of cardiac impairment or hypertension were
observed.
Initially, JNJ-26483327 was administered as oral solution, but
as high amounts of the vehiculum Captisol have been noted to
induce soft stools or diarrhoea in man, a capsule formulation was
introduced for the higher dose levels (X1200mg). The maximum
drug load of JNJ-26483327 was 300mg per capsule, resulting in a
substantial capsule intake at the higher dose levels. At 2100mg
BID grade 3 anorexia and a combination of grade 3 anorexia and
fatigue yielded protocol-defined DLT in two patients, but because
of substantial difficulty with capsule intake experienced by all
other patients at this dose, capsule load at 2100mg BID was
considered dose limiting as well, albeit not defined by protocol.
Therefore, the recommended phase 2 dose for JNJ-26483327 was
set at 1500mg BID.
Pharmacokinetic analysis showed rapid absorption with Cmax
reached on average 1–2h earlier in case of the solution. With a
half-life of 5–8h, the drug is suitable for BID dosing. Up to
1500mg, Cmax and AUC were dose proportional at steady state
(day 28) albeit with substantial inter- and intrapatient variability.
This is a common phenomenon for many oral TKIs. Steady-state
plasma concentrations at 1500mg were in the active range as
observed in mouse xenograft models. The PK data support the
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Figure 2 Mean plasma concentration–time profile of JNJ-26483327 after administration of JNJ-26483327 orally BID, days 1 and 28.
Table 4 Pharmacokinetic parameters of JNJ-26483327 for days 1 and 28 (steady state)
Doses (BID) Day Patients (n) AUC (nghml
 1)
a Cmax (ngml
 1) tmax (h) t1/2 (h) CL/F (lh
 1) Vdz/F (l)
800mg 1 3 10621±5230 2210±593 2.03 (2.00–3.02) 8.4±1.8 86.3±33.5 1021±401
28 2 10623 2390 1.52 (1.00–2.03) 76.4
1200mg 1 3 35554±22086 3707±1927 3.00 (2.00–6.00) 5.2±1.7 47.4±35.3 342±212
28 2 21230 2750 1.00 (1.00–1.00) 88.4
1500mg 1 6 16388±11956 2361±1765 4.00 (2.00–4.03) 4.8±0.5 144±104 1038±799
28 6 26225±20491 3375±2116 3.99 (3.00–12.00) 286±540
2100mg 1 4
a 20357±25622 2213±2983 3.54 (2.00–4.08) 6.7±1.7 3055±5099 36985±62264
28 2 8467 1236 5.00 (4.00–6.00) 3087
tmax, median (min–max); Cmax, AUC, t1/2, CL/F, Vdz/F: mean±s.d. s.d.¼standard deviation, given when data of 42 subjects. AUCinf after the first dose and AUCtau at steady
state (day 28).
an¼3 for AUCinf, t1/2, CL/F and Vdz/F.
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should be 1500mg BID, as the pharmacokinetic profile at 2100mg BID
showed lower overall drug exposure, probably because of a decrease in
bioavailability. Very low concentrations were observed in one specific
subject after 2100mg administration, which could account for the
overall effect observed at this dose level; of note is that this subject had
taken carbamazepine, a known inducer of CYP3A4.
Somewhat to our surprise, no clear JNJ-26483327-induced
pharmacodynamic effects were observed in surrogate tissues in
this study. No consistent histopathological effects were observed in
skin biopsies and various biomarkers of EGFR-signalling and
serum levels of regulators of (tumour-)angiogenesis also remained
essentially unchanged, even in patients experiencing obvious on-
target side effects such as diarrhoea and skin rash. As skin toxicity
is a predominant side effect of many specific EGFR-TKI (Li and
Perez-Soler, 2009), the question here is whether any of the other
target inhibiting effects acts as main driver of the therapeutic
potential of JNJ-26483327. As JNJ-26483327 indeed targets multiple
tyrosine kinases, this is a possible explanation. Another question
is whether other parameters such as inflammatory cytokines
(e.g. IL-1b, IL-6, IL-8), placental growth factor or circulating
tumour cells should have been explored to gain better insight in
pharmacodynamic alterations at the tumoural level (Jain et al,
2009). In addition, our observations again stress the importance of
performing pharmacodynamic research in the most essential tissue
available, being the tumour. Although taking repeated tumour
biopsies will be inconvenient or even somewhat cumbersome for
patients, restricting pharmacodynamic research to surrogate
tissues might lead to disappointing or even incorrect conclusions.
In our study, 32% of the patients had stable disease for more
than two cycles, with a maximum of six cycles over a dose range of
800–2100mg BID. Although there was no statistical correlation
between dose and frequency and/or duration of disease stabilisa-
tion, the observation was that at doses of and exceeding 1500mg
BID more prolonged disease stabilisation was observed. Some
cases of prolonged stable disease were observed; however, because
of the small numbers, no recommendation as to which tumour
type could benefit most of JNJ-26483327 administration can be
made. Most prolonged disease stabilisation was seen in two
patients with prostate and renal cell cancer, respectively. If in
future studies with JNJ-26483327 at these dose levels a better
correlation between clinical outcome and pharmacodynamic
assessment could be made, this would undoubtedly help in better
understanding this broad-spectrum TKI.
In summary, JNJ-26483327 is a novel multi-targeted TKI.
It is well tolerated at the recommended dose level of 1500 BID
with only mild and reversible gastrointestinal and skin toxicity.
At this dose, JNJ-26483327 shows a predictable pharmacokinetic
profile. Further studies to establish its clinical antitumour activity
are currently being considered.
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